The Tranexamic Acid Market was valued at USD 1.03 Billion in 2024. The Tranexamic Acid Market industry is projected to grow from USD 1.10 Billion in 2025 to USD 1.86 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.38% during the forecast period (2025-2035).
The Increasing Surgical Procedures and Growing Prevalence of Trauma Cases and Growing Prevalence of Heavy Menstrual Bleeding (HMB) are driving the growth of the Tranexamic Acid Market.
As per the Analyst at MRFR, the rising number of surgical procedures worldwide is a key factor driving the growth of the Tranexamic Acid Market. The increasing prevalence of chronic diseases such as cardiovascular disorders, orthopedic conditions, and cancer has significantly contributed to the rising demand for surgical interventions. As more patients undergo surgeries ranging from coronary artery bypass grafting (CABG) and joint replacements to tumor resections and cesarean deliveries, the need for effective blood management solutions has intensified.”
FIGURE 1: TRANEXAMIC ACID MARKET VALUE (2019-2035) USD BILLION
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The increasing preference for non-surgical and minimally invasive treatment approaches is a major driver for the Tranexamic Acid Market. Patients and healthcare providers are shifting toward pharmacological solutions that offer effective treatment without the risks and complications associated with surgical procedures. Tranexamic acid, being a well-established antifibrinolytic agent, is widely used to manage various bleeding disorders, trauma cases, and surgical interventions. Its growing adoption in the management of heavy menstrual bleeding (HMB), trauma-related hemorrhage, and dermatological conditions is opening new avenues for market expansion.
One of the key applications of tranexamic acid in this domain is its use in heavy menstrual bleeding (HMB). With an increasing number of women experiencing abnormal uterine bleeding (AUB) due to hormonal imbalances, uterine fibroids, and other gynecological conditions, there is a growing need for effective, non-surgical treatment options. Tranexamic acid has emerged as a first-line pharmacological therapy, helping women reduce excessive menstrual blood loss without undergoing invasive procedures like endometrial ablation or hysterectomy. Its oral and injectable formulations provide flexibility, improving patient compliance and treatment outcomes.
The demand for non-surgical management of trauma-induced bleeding is also increasing, particularly in emergency and battlefield medicine. Tranexamic acid is a critical component of trauma care protocols worldwide, significantly reducing mortality by preventing excessive blood loss following accidents, surgeries, or postpartum hemorrhage (PPH). The inclusion of tranexamic acid in pre-hospital emergency response systems has enhanced its adoption in ambulatory care and paramedic services, further expanding its market potential.
Based on the Formulation Type, the Tranexamic Acid Market has been bifurcated into Oral, Injectable, and Topical. The Oral segment accounted for the largest market share of USD 0.49 Billion in 2024 and is likely to register a CAGR of 5.83% during the projected period. On the other hand, Injectable segment will likely register a CAGR of 5.02% during the projected period. Oral tranexamic acid is one of the most widely used formulations due to its ease of administration, high patient compliance, and affordability. This formulation is extensively prescribed for the treatment of heavy menstrual bleeding (menorrhagia), which affects a significant proportion of women globally.
According to the American College of Obstetricians and Gynecologists (ACOG), nearly one in three women experience excessive menstrual bleeding, and oral tranexamic acid has emerged as an effective first-line treatment option. Unlike hormonal therapies, which may have long-term side effects, tranexamic acid offers a safer alternative with minimal hormonal interference. Additionally, the oral formulation is commonly used to reduce postoperative bleeding in dental, orthopedic, and cardiovascular surgeries, significantly lowering the need for blood transfusions.
The affordability and availability of tablet and capsule formulations make them a preferred choice in developing economies, where access to advanced surgical interventions is often limited. For instance, in India and Southeast Asian countries, oral tranexamic acid is a widely prescribed medication in gynecology and general surgery departments. Additionally, the growing awareness of self-medication and over the counter (OTC) drugs has fueled the demand for oral formulations. Several pharmaceutical companies, including Sanofi and Pfizer, are expanding their product lines to cater to the increasing demand for this formulation.
Based on the Application, the Tranexamic Acid Market has been classified into Menorrhagia, Surgical Bleeding Control, Trauma and Injury, Hereditary Angioedema (HAE), Postpartum Hemorrhage, and Others. The Menorrhagia segment accounted for the largest market share of USD 0.61 in 2024 and is likely to register a CAGR of 5.88% during the projected period. On the other hand, the surgical bleeding control segment will likely register a CAGR Of 4.76% during the projected period.
Menorrhagia, or excessive menstrual bleeding, is one of the most common indications for tranexamic acid (TXA) usage, significantly impacting millions of women worldwide. It is characterized by heavy or prolonged menstrual bleeding that can lead to iron deficiency anemia, fatigue, and reduced quality of life. According to the American College of Obstetricians and Gynecologists (ACOG), nearly one in five women experience heavy menstrual bleeding, making it a significant public health concern. Tranexamic acid works by inhibiting plasminogen activation and stabilizing blood clots, thereby reducing menstrual blood loss by up to 50% in affected individuals. Unlike hormonal treatments such as oral contraceptives or intrauterine devices (IUDs), TXA provides a non-hormonal alternative, making it particularly beneficial for patients who cannot tolerate hormonal therapies. The increasing prevalence of menorrhagia and growing awareness about non-hormonal treatment options have.
Based on the End User, the Tranexamic Acid Market has been classified into Hospitals & Clinics, Ambulatory Surgical Centers, and Others. The hospitals segment accounted for the largest market share of USD 0.46 in 2024 and is likely to register a CAGR of 5.23% during the projected period. On the other hand, the Ambulatory Surgical Centers (ASCs) segment will likely register a CAGR of 4.96% during the projected period. Hospitals and clinics represent the largest end-user segment of the global tranexamic acid (TXA) market due to the widespread use of TXA in surgical procedures, trauma management, and obstetric emergencies.
These healthcare facilities rely on TXA to prevent and control excessive bleeding in various medical interventions, making it a crucial component of hospital formularies. TXA is extensively used in major surgical departments, including cardiology, orthopedics, gynecology, and neurosurgery, where blood loss management is critical. According to the American Society of Hematology (ASH), hospitals have reported a significant reduction in blood transfusion rates, by approximately 30-50%, in surgical patients administered with TXA, highlighting its essential role in blood conservation strategies.
In emergency and trauma care settings, hospitals deploy TXA as a first-line intervention for hemorrhagic shock. The CRASH-2 trial, conducted by the London School of Hygiene & Tropical Medicine, demonstrated that administering TXA within three hours of severe trauma reduced mortality by nearly 15%. This has led to TXA being included in hospital emergency protocols and pre-hospital ambulance services worldwide. Additionally, major health organizations such as the World Health Organization (WHO) and the National Institute for Health and Care Excellence (NICE) recommend TXA administration in emergency settings, further strengthening its adoption in hospitals.
FIGURE 2: TRANEXAMIC ACID MARKET SHARE BY END USER 2024 AND 2035 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Based on the Region, the global Tranexamic Acid is segmented into North America, Europe, Asia-Pacific and Rest of the World. The North America dominated the global market in 2024, while the Asia Pacific is projected to be the fastest–growing segment during the forecast period. Major demand factors driving the North America market are North America dominates the global tranexamic acid (TXA) market, driven by advanced healthcare infrastructure, a high volume of surgical procedures, and increasing awareness regarding blood loss management.
The United States and Canada have been at the forefront of TXA adoption due to the rising number of trauma-related injuries, increasing surgical interventions, and supportive regulatory policies. The Centers for Disease Control and Prevention (CDC) reports that over 50 million major surgeries are performed annually in the U.S., many of which require effective perioperative blood management strategies. TXA has gained widespread use in orthopedic, cardiac, trauma, and obstetric surgeries, leading to reduced blood transfusion rates and improved patient outcomes.
Additionally, government initiatives promoting patient blood management (PBM) programs have significantly contributed to TXA's market expansion. The region's high incidence of trauma cases and emergency care admissions has further accelerated the demand for TXA. According to the National Highway Traffic Safety Administration (NHTSA), more than 6 million traffic accidents occur annually in the U.S., with a substantial number resulting in life-threatening hemorrhagic injuries. TXA has become a standard treatment in prehospital trauma care, with paramedics administering it to reduce the risk of mortality from excessive bleeding. Moreover, the U.S. military has incorporated TXA into battlefield medicine protocols, leveraging its life-saving potential in combat zones and mass casualty incidents.
FIGURE 3: TRANEXAMIC ACID MARKET VALUE BY REGION 2024 AND 2035 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Further, the countries considered in the scope of the Application Tracking System Market are the US, Canada, Germany, France, UK, Spain, Italy, Rest of Europe, China, India, Japan, South Korea, Australia, Rest of Asia Pacific, Middle East, Africa, Latin America and others.
Global Tranexamic Acid Key Market Players & Competitive Insights
Many global, regional, and local vendors characterize the Tranexamic Acid Market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.
The major competitors in the market are Ferrero International Pfizer Inc, Fresenius Kabi Usa, LLC, Teva Pharmaceutical Industries Ltd, MAXWELLIA Ltd, Aurobindo Pharma Usa, Sun Pharmaceutical Industries Ltd, APOTEX Inc, Ferring Pharmaceuticals, Nordic Pharma, Inc, EXELA Pharma Sciences LLC, are among others. The Tranexamic Acid Market is a consolidated market due to increasing competition, acquisitions, mergers and other strategic market developments and decisions to improve operational effectiveness.
| Report Attribute/Metric | Details |
| Market Size 2024 | USD 1.03 Billion |
| Market Size 2025 | USD 1.10 Billion |
| Market Size 2035 | USD 1.86 Billion |
| Compound Annual Growth Rate (CAGR) | 5.38% (2025-2035) |
| Base Year | 2024 |
| Forecast Period | 2025-2035 |
| Historical Data | 2019-2023 |
| Forecast Units | Value, (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | By Formulation Type, By Application, By End User |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The US, Canada, Germany, France, the UK, Spain, Italy, Rest of Europe, China, India, Japan, South Korea, Australia, Rest of Asia Pacific, Middle East, Africa, and Latin America. |
| Key Companies Profiled | Ferrero International Pfizer Inc, Fresenius Kabi Usa, LLC, Teva Pharmaceutical Industries Ltd, MAXWELLIA Ltd, Aurobindo Pharma Usa, Sun Pharmaceutical Industries Ltd, APOTEX Inc, Ferring Pharmaceuticals, Nordic Pharma, Inc, EXELA Pharma Sciences LLC |
| Key Market Opportunities | · Rising demand for minimally invasive & non-surgical treatment options · Untapped potential in emerging markets |
| Key Market Dynamics | · Increasing surgical procedures · Growing prevalence of trauma cases |
Frequently Asked Questions (FAQ) :
USD 1.03 Billion is the Tranexamic Acid Market in 2024
The Menorrhagia segment by Application holds the largest market share and grows at a CAGR of 4.29% during the forecast period.
North America holds the largest market share in the Tranexamic Acid Market.
Ferrero International Pfizer Inc, Fresenius Kabi Usa, LLC, Teva Pharmaceutical Industries Ltd, MAXWELLIA Ltd, Aurobindo Pharma Usa, Sun Pharmaceutical Industries Ltd, APOTEX Inc, Ferring Pharmaceuticals, Nordic Pharma, Inc, EXELA Pharma Sciences LLC are prominent players in the Tranexamic Acid Market.
The Oral segment dominated the market in 2024.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
